Share Twitter LinkedIn Facebook Email Jennifer Brown, MD of Dana Farber, discusses a current and promising trial that combines ibrutinib with a standard chemo-immunotherapy combination: fludarabine, cyclophosphamide, rituximab (FCR), at the 58th ASH Annual Meeting in San Diego, CA.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read